Portal de Periódicos da CAPES

Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure–activity relationship

2010; Elsevier BV; Volume: 19; Issue: 3 Linguagem: Inglês

10.1016/j.bmc.2010.12.027

1464-3391

Jin Xie, Gennadiy Poda, Yiding Hu, Natalie X. Chen, Richard F. Heier, Serge G. Wolfson, Matthew T. Reding, Patrick J. Lennon, Ravi G. Kurumbail, Shaun R. Selness, Xiong Li, Nandini Kishore, Cynthia D. Sommers, Lori J. Christine, Sheri L. Bonar, Neetu Venkatraman, Sumathy Mathialagan, Sarah J. Brustkern, H. T. Huang,

Bioactive Compounds and Antitumor Agents

Installation of sites for metabolism in the lead compound PHA-767408 was the key focus of the IKK-2 inhaled program. This paper reports our efforts to identify a novel series of aminopyridinecarboxamide-based IKK-2 inhibitors, which display low nanomolar potency against IKK-2 with long duration of action (DOA), and metabolically labile to phase I and/or phase II metabolizing enzymes with potential capability for multiple routes of clearance. Several compounds have demonstrated their potential usefulness in the treatment of asthma and chronic obstructive pulmonary disease (COPD).